How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

CDK Inhibitors in Oncology: Emerging Opportunities and Translational Models for Drug Development

calendar_today November 4, 2026 person david.vallerand@crownbio.com (David Vallerand, PhD) domain crownbio

Cyclin-dependent kinases (CDKs) regulate cell-cycle progression and have long been investigated as therapeutic targets in oncology. The clinical success of selective CDK4/6 inhibitors in breast cancer established the therapeutic value of CDK inhibition. However, despite more than a decade of research, resistance, off-target effects, and limited efficacy in other tumor types have restricted their broader use as antitumor therapies.

open_in_new Read original post